GLP-1 Medications and Your Mental Health: What Ozempic, Wegovy, and Mounjaro Are Doing to Your Mood and Relationships

Medications such as Ozempic, Wegovy, and Mounjaro have transformed the treatment of type 2 diabetes and obesity, and millions of people now use them to manage their weight and metabolic health. What receives less attention, however, is the effect these medications may have on mood, emotional regulation, and personal relationships. As GLP-1 receptor agonists become part of everyday clinical practice, it is worth understanding what the current research says and what patients and their loved ones should watch for.

How GLP-1 Medications Work

GLP-1 receptor agonists, which include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), mimic a hormone that regulates appetite, insulin secretion, and digestion. Beyond their metabolic effects, these medications act on receptors in the brain, including regions involved in reward processing and mood regulation. This is one reason researchers have taken a close look at their psychiatric effects; a medication that changes brain chemistry related to appetite and reward may also influence emotional experience more broadly.

What the Research Actually Shows About Mood

The research on GLP-1 medications and mental health has been genuinely mixed, and it continues to evolve as more patients use these medications long-term.

Some patients report new or worsening mood symptoms, including low mood, anxiety, irritability, and a sense of emotional flatness, within weeks of starting treatment or after a dose increase. These reports are worth taking seriously on an individual level, even though they do not appear consistently across large studies. Several sizable studies point in a different direction entirely. A Swedish national cohort study found that certain GLP-1 medications, semaglutide in particular, were associated with a reduced risk of psychiatric decline in patients who already had depression or anxiety. A separate 2024 study of patients without a known psychiatric history found no increased likelihood of developing depression, and even showed a small but statistically significant reduction in depressive symptoms over the course of treatment.

A 2026 meta-analysis added further nuance, finding that GLP-1 medications were associated with a modest improvement in overall psychological well-being across randomized trials, though not with a significant change in depressive symptoms specifically. Taken together, the evidence suggests that GLP-1 medications are neutral to modestly beneficial for mood in most patients, including many with a pre-existing mood or anxiety disorder. At the same time, individual responses vary, and a meaningful subset of patients does experience mood changes that warrant clinical attention rather than being dismissed as an expected side effect of weight loss.

Signs Worth Discussing With a Provider

Because individual experiences differ from what a population-level study can predict, patients starting or adjusting a GLP-1 medication should monitor for the following and should raise any of them with their prescriber or a mental health professional promptly.

• Persistent sadness, hopelessness, or loss of interest in activities that previously brought enjoyment
• New or worsening anxiety, irritability, or a sense of emotional flatness
• Noticeable changes in sleep, energy, or motivation that are not explained by appetite or weight changes alone
• Any thoughts of self-harm or suicide, which should be treated as an emergency

Patients should tell their health care professional about any new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior. Anyone experiencing suicidal thoughts can call or text 988 to reach the Suicide and Crisis Lifeline at any hour.

The Relationship and Identity Piece

The psychiatric literature on GLP-1 medications has focused largely on depression and anxiety, but clinicians are increasingly attentive to a quieter set of changes that affect relationships and self-concept. Psychologists working with GLP-1 patients report helping them manage body image, identity, and relationship changes that accompany rapid weight loss.

Rapid changes in appetite, often described by patients as reduced “food noise,” can shift the role food plays in social gatherings, family routines, and cultural traditions built around meals. Some patients describe friction with partners or family members who eat differently than they now do, or discomfort when their changing body draws unsolicited comments from others. Others notice shifts in self-image that outpace their emotional adjustment to a new body, which can surface old insecurities or complicate an existing relationship with food and body image. None of this is a sign that something has gone wrong with treatment. It reflects the reality that a medication affecting appetite and weight will also touch identity, habits, and relationships that were built around the old status quo. Naming these changes early, ideally before starting treatment, tends to make the adjustment considerably smoother.

Treatment Approaches

For patients who experience mood changes while taking a GLP-1 medication, the most effective response is coordinated care rather than a choice between stopping the medication and quietly enduring the symptoms.

A mental health evaluation can help determine whether new mood symptoms are related to the medication, to the psychological adjustment of significant weight change, to an underlying condition that existed before treatment began, or to some combination of these factors. From there, treatment may include psychotherapy focused on body image and identity adjustment, evidence-based treatment for any emerging or worsening depression or anxiety, and close communication between the prescribing physician and the mental health provider so that any medication adjustments are made safely and thoughtfully.

For patients with a pre-existing mood or anxiety disorder considering a GLP-1 medication, a pre-treatment consultation can help establish a baseline and a monitoring plan from the outset.

A Note for Loved Ones

Family members and partners are often the first to notice a shift in mood, energy, or behavior, sometimes before the patient themselves recognizes it. If you notice a loved one on a GLP-1 medication becoming withdrawn, unusually irritable, or uncharacteristically low, a direct and caring conversation is worthwhile. Encouraging them to raise the change with their prescriber, rather than assuming it will pass on its own, can make a meaningful difference.

Get Support at Blair Wellness Group

Starting a GLP-1 medication is a significant physical and emotional transition, and you do not have to navigate the mood and relationship changes that can come with it alone. If you or someone you love has noticed shifts in mood, anxiety, or emotional well-being while taking Ozempic, Wegovy, Mounjaro, or a similar medication, the clinicians at Blair Wellness Group are here to help. Contact us today to schedule an evaluation and build a care plan that supports both your physical and mental health.